stockrow
Friday 6 November 2026
Export INCR’s income statement to Excel — free account
InterCure Ltd.
INCR Healthcare Drug Manufacturers Specialty & Generic
InterCure Ltd.’s revenue for fiscal 2025 (year ended December 2025) was $78.5 million, up 18.4% from fiscal 2024.
3.36
0.06
+1.82%
Follow INCR
Alert me
| Jun '25 | Jun '24 | Jun '23 | Mar '23 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
— | — | — | 4 |
+8 more TTM periods Free account |
| 0.00% | 0.00% | 3.98% | 6.15% | ||
| 0.00% | 0.00% | 2.51% | 3.84% | ||
ROIC |
0.00% | 0.00% | 0.00% | 3.89% | |
Return on Tangible Assets |
0.00% | 0.00% | 7.54% | 11.08% | |
Average Days of Receivables |
0.00 | 0.00 | 111.81 | 143.21 | |
Free Cash Flow per Share |
0.00 | — | 0.00 | (0.49) | |
Free Cash Flow |
(0.81) | — | — | (4.17) | |
Capital Expenditures |
(3.72) | — | — | (3.92) | |
| Other line items | |||||
Cash ROIC |
(0.48%) | 0.00% | 0.00% | (1.76%) | |
Accounts Receivable Turnover |
0.00 | 0.00 | 4.10 | 3.85 | |
Accounts Payable Turnover |
0.00 | 0.00 | 3.01 | 2.90 | |
Inventory Turnover |
0.00 | 0.00 | 2.35 | 2.31 | |
Average Days of Payables |
0.00 | 0.00 | 129.41 | 130.24 | |
Days of Inventory on Hand |
0.00 | 0.00 | 177.53 | 179.57 | |
Tax Rate |
— | — | 2.86 | 0.13 | |
Research and Development Expense of Revenue |
— | — | 0.13% | 0.15% | |
Selling, General and Administrative Expense of Revenue |
— | — | 26.05% | 25.97% | |
Share Based Compensation of Revenue |
0.00% | — | 0.00% | 2.28% | |
Interest Coverage |
— | — | 0.00 | 0.95 | |
Operating CF/Net income |
0.00 | — | 0.00 | (0.03) | |
Depreciation/Fixed assets |
0.18 | 0.00 | 0.00 | 0.13 | |
Capex/Depreciation |
(0.69) | — | — | (1.07) | |
Revenue per Share |
— | — | 0.00 | 14.26 | |
Operating CF per Share |
0.00 | — | 0.00 | (0.03) | |
Capex per Share |
0.00 | — | 0.00 | (0.46) | |
Capex to Sales |
0.00 | — | 0.00 | 0.03 |
Columns are period end dates · fundamentals updated 26 Oct 2026